UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5

Jerusalem, Israel 9777605

+972 (3) 577-4115

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Alpha Tau Medical Ltd. (the “Company”) ~~presented~~hereby ~~certain~~furnishes ~~interim clinical data from its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as~~ the ~~REGAIN~~following ~~(Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial, during a conference call and webcast held on May 11, 2026, at 8~~documents:30 a.m. Eastern Time and such information was also made available in the presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of May 11, 2026 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

~~The~~(i) ~~information~~notice ~~in this Report on Form 6-K, including in Exhibit 99.1 attached hereto is being furnished~~ and ~~shall~~proxy ~~not~~statement bewith ~~deemed~~respect ~~“filed”~~to ~~for~~ the ~~purposes~~Company’s ofannual ~~Section~~general 18meeting of ~~the~~shareholders ~~Securities Exchange Act of 1934, as amended~~ (the “~~Exchange Act~~Meeting”), orto ~~otherwise~~be ~~subject~~held toat ~~the~~4:00 ~~liabilities~~p.m. of(Israel ~~that Section~~time), ~~nor~~on ~~shall it~~June be23, ~~deemed~~2026, ~~incorporated~~at bythe ~~reference~~Company’s inheadquarters ~~any~~at ~~filing~~5 ~~made~~Kiryat byHamada ~~the~~St., ~~Company~~Jerusalem ~~under~~9777605, ~~the~~Israel, ~~Securities~~describing ~~Act~~proposals ofto ~~1933,~~be asvoted ~~amended,~~upon orat the ~~Exchange Act~~Meeting, ~~except~~the asprocedure ~~otherwise~~for ~~set~~voting ~~forth~~in ~~herein~~person or asby ~~shall~~proxy beat ~~expressly~~the ~~set~~Meeting ~~forth~~and byvarious ~~specific~~other ~~reference~~details inrelated ~~such~~to athe ~~filing.~~Meeting; and

(ii)	a proxy card for use in connection with the Meeting.

The proxy statement is furnished with this report of foreign private issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1 and the proxy card is furnished with this Form 6-K as Exhibit 99.2.

This Report and the related exhibits are incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-274457, 333-288240 and 333-295359) and Form S-8 (File Nos. 333-264169, 333-270406, 333-277733, 333-285745 and 333-294151).

EXHIBIT INDEX

Exhibit No.		Description
99.1		Notice and proxy statement for the annual general meeting of shareholders of the Company ~~Presentation.~~to be held on June 23, 2026
99.2		Proxy card to be mailed for the annual general meeting of shareholders of the Company to be held on June 23, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Alpha Tau Medical Ltd.
Date: May 11, 2026	By:	/s/ Uzi Sofer
Date: May 18, 2026	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

Filing Compare · Alpha Tau Medical Ltd.